021-51111890
购物车（）
sales@molnova.cn
Lirilumab
CAS No. 1000676-41-4
Lirilumab ( —— )
产品货号. M36889 CAS No. 1000676-41-4
Lirilumab (IPH2102) 是一种 anti-KIR 单克隆抗体，其具有抗肿瘤活性。Lirilumab 可用于白血病、头颈部鳞状细胞癌 (SCCHN) 的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥5216 | 有现货 |
|
| 10MG | ￥7106 | 有现货 |
|
| 25MG | ￥10137 | 有现货 |
|
| 50MG | ￥13764 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lirilumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Lirilumab (IPH2102) 是一种 anti-KIR 单克隆抗体，其具有抗肿瘤活性。Lirilumab 可用于白血病、头颈部鳞状细胞癌 (SCCHN) 的研究。
-
产品描述Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
-
体外实验——
-
体内实验Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells Dosage:15 mg/kg Administration:intravenous injection; 15 mg/kg; once Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Virus Protease
-
研究领域——
-
适应症——
化学信息
-
CAS Number1000676-41-4
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.?
产品手册
关联产品
-
Xanthoangelol
Xanthoangelol, which can be extracted from Angelica keiskei, inhibits obesity-induced inflammatory responses.Xanthoangelol has antimicrobial activity, inhibits monoamine oxidase, and induces apoptosis in neuroblastoma and leukemia cells.
-
Tyr-ACTH (4-9)
Tyr-ACTH (4-9) 是一种行为活性肽。Tyr-ACTH(4-9) 可用于大鼠学习行为的消除研究。
-
(Tyr0)-Melanocyte-St...
(Tyr0)-Melanocyte-Stimulating Hormone-Release Inhibiting Factor
